Single fraction boost with high dose rate interstitial brachytherapy in conservative treatment of breast carcinoma;Sobreimpresión en fracción única con braquiterapia intersticial de alta tasa en el tratamiento conservador del carcinoma de mama

Clinical and Translational Oncology

Volumn 7, Issue 9, 2005, Pages 404-408

  Tortajada, Inmaculada Beato ^a   Rodríguez, Jose Luis Guinot ^a   Alpuente, Leoncio Arribas ^a   Martos, Manuel Aguayo ^a   Pérez, María Carrascosa ^a   Azcutia, Maribel Tortajada ^a   Pérez, Pedro Pablo Escolar ^a   Martín, María Maroñas ^a   Vicente, Marisa Chust ^a   Cloquell, José Luis Mengual ^a   Ayet, Carmen Pesudo ^a   Giner, Manuel Casaña ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Boost; Brachytherapy; Breast; High dose rate

Indexed keywords

ADULT; AGED; ARTICLE; BRACHYTHERAPY; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; METHODOLOGY; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; RADIATION DOSE; SEGMENTAL MASTECTOMY;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE;

EID: 33644805111     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/BF02716586     Document Type: Article

References (19)

1. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of followup in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333:1456-61.
2. Early Breast Cancer Trialists'Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med. 1995;333:1444-55.
3. Van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Nat Cancer Inst. 2000;92:1143-50.
4. Romestaing P, Lehingue Y, Carrie C, et al. Role of 10 Gy boost in the Conservative Treatment or early Breast Cancer: results of randomized Clinical Trial In Lyon, France. J Clin Oncol. 1997;15:963-8.
5. Pérez CA, Taylor ME, Halverson K, García D, Kuske RR, Lockett MA. Brachytherapy or electron beam boost in conservation therapy of carcinoma of the breast: a nonrandomized comparison. Int J Radiation Oncol Biol Phys. 1996;34(5):995-1007.
6. Frazier RC, Kestin LL, Kini V, et al. Impact of boost technique on outcome in early-stage cancer patients treated with breast -conserving therapy. Am J Clin Oncol. 2001; 24(1):26-32.
7. Moreno F, Guedea F, López Y, et al. External beam irradiation plus (192) Ir implant after breast-preserving surgery in women with early breast cancer. . Int J Radiation Oncol Biol Phys. 2000;48(3):757-65.
8. G Miragall E, Guinot JL, Arribas L, et al. Long term results in positive margin conservative breast cancer treatment with brachytherapy. Proceedings of 10th International Brachytherapy Conference. 2000 November 11-14 Madrid.
9. Hammer J, Seewald DH, Track C, Zoidl JP, Labeck W. Breast Cancer: Primary Treatment with external-Beam Radiation Therapy and High-Dose-Rate Iridium Implantation. Radiology. 1994;193:573-7.
10. Hennequin C, Durdux C, Espié M, et al. High-Dose-Rate brachytherapy for early breast cancer: an ambulatory technique. Int J Radiation Oncology Biol Phys. 1999; 45:85-90.
11. Guedea F, Arribas L. Conferencia de consenso sobre la braquiterapia en cáncer de mama en estadios iniciales. Rev Oncol. 2003;5(7):413-8.
12. Manning MA, Arthur DW, Schmidt-Ullrich RK, Arnfield M, Amir C, Zwicker R. Interstitial High-Dose-Rate brachytherapy boost: the feasibility and cosmetic outcome of a fractionated outpatient delivery scheme. Int J Radiation Oncol Biol. Phys. 2000;48:1301-6.
13. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001;345:1378-87.
14. Vrieling C, Collette L, Fourquet A, et al. Can patient, treatment and pathology- related characteristics explain the high local recurrence rate following breast-conserving therapy in young age? European J Cancer. 2003;3:378-90.
15. Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19:1688-97.
16. Wazer DE, Schmidt-Ullrich RK, Ruthazer R, et al. Factors determining outcome for breast-conserving irradiation with margin-directed dose escalation to the tumor bed. Int J Radiation Oncol Biol Phys. 1998;40(4):851-8.
17. Kurtz J. Which patients don't need a tumor-bed boost after whole-breast radiotherapy. Strahlenther Onkol. 2001; 177:33-6.
18. Hughes K, Schanaper A, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971-7.
19. Vázquez C, Sancho MF, Campos J, et al. Tratamiento conservador en el cáncer de mama. Análisis de 451 pacientes con seguimiento mínimo de 5 años. Oncología. 2000;23(2):77-84.